Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress DisorderGlobeNewsWire • 09/04/19
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant RejectionGlobeNewsWire • 08/21/19
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSDGlobeNewsWire • 08/20/19
Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause'Market Watch • 04/19/19